Trending menu:
Comment
-
22 August 2019
Gene therapy pipeline for neurology indications dominated by viral vectors
Of the 38 pipeline products that are currently in development stages, AAV-based delivery platforms account for 45% of these products.
-
20 August 2019
Improved clinical efficacy found wanting in Phase III IMPALA trial
This key finding has shaped the future direction for the drug as Mologen AG has confirmed that it will only pursue combination studies.
-
20 August 2019
New, efficacious options offer hope for Ebola treatment and containment
While there are currently no therapeutic options for Ebola, preliminary data from a clinical trial in the DRC that compared four drugs for the treatment of Ebola showed promising results.
-
19 August 2019
Aurinia still has potential Phase III lupus nephritis mortality risk
Lupus nephritis is an inflammation of the kidney caused by systemic lupus erythematosus.
-
14 August 2019
Zolgensma and Spinraza may face spinal muscular atrophy market shortfall
Spinraza and Zolgensma are involved in ongoing clinical trials in presymptomatic treatment of spinal muscular atrophy patients, providing stronger evidence for physicians to recommend using these treatments.
-
15 July 2019
Trials data suggests Cosentyx from Novartis will change psoriasis market
Cosentyx is set to change the landscape of the psoriasis market following results published by Novartis from a phase II study,
-
29 May 2019
Clinical trials landscape for type 2 diabetes analysed
An analysis of the number of type 2 diabetes clinical trials with a start date of between 1 January and 31 December 2018.
-
20 May 2019
Ulcerative colitis clinical trials analysed over the last five years
An analysis of ulcerative colitis clinical trials as reported by the GlobalData Clinical Trials database.
-
1 May 2019
Top ten drugs in biosimilar trials globally
The number one drug in biosimilar clinical trials by count is adalimumab biosimilar, referencing the branded biologic Humira.
-
10 April 2019
Governments are playing a bigger role in cell and gene therapy manufacturing
Currently, the UK accounts for 16% of global cell therapy manufacturing facilities, according to GlobalData’s Contract Service Provider Database.